Showing results (1-10 of 14) with videos related to
Sort By:
Pageof 2
Cancers|July 2, 2020
Targeting the Redox Landscape in Cancer TherapyDilip Narayanan, Sana Ma, Dennis ÖzcelikChemical Biology & Drug Design|June 11, 2013
Evaluating the predictivity of virtual screening for ABL kinase inhibitors to hinder drug resistanceOsman A B S M Gani, Dilip Narayanan, Richard A EnghJournal of Cheminformatics|November 1, 2017
Data driven polypharmacological drug design for lung cancer: analyses for targeting ALK, MET, and EGFRDilip Narayanan, Osman A B S M Gani, Franz X E Gruber, et al.Chemmedchem|July 3, 2026
Discovery of Ligands for the TNFR1 Extracellular Domain Using Fragment-Based Drug DiscoveryHenri Chédotal, Katrine Povlsen, Dilip Narayanan, et al.Drug Discovery Today|April 1, 2023
Small-molecule modulators of tumor necrosis factor signalingHenri Chédotal, Dilip Narayanan, Katrine Povlsen, et al.Biochimica Et Biophysica Acta|May 24, 2015
Assessing protein kinase target similarity: Comparing sequence, structure, and cheminformatics approachesOsman A Gani, Balmukund Thakkar, Dilip Narayanan, et al.Journal of Medicinal Chemistry|January 11, 2020
Developing Inhibitors of the p47phox-p22phox Protein-Protein Interaction by Fragment-Based Drug DiscoverySara Marie Øie Solbak, Jie Zang, Dilip Narayanan, et al.Journal of Medicinal Chemistry|August 15, 2019
A Comparative Assessment Study of Known Small-Molecule Keap1-Nrf2 Protein-Protein Interaction Inhibitors: Chemical Synthesis, Binding Properties, and Cellular ActivityKim T Tran, Jakob S Pallesen, Sara M Ø Solbak, et al.Journal of Medicinal Chemistry|October 17, 2024
Structure-Guided Conformational Restriction Leading to High-Affinity, Selective, and Cell-Active Tetrahydroisoquinoline-Based Noncovalent Keap1-Nrf2 InhibitorsYuting Qin, Cecilie Poulsen, Dilip Narayanan, et al.Journal of Medicinal Chemistry|October 20, 2022
Development of Noncovalent Small-Molecule Keap1-Nrf2 Inhibitors by Fragment-Based Drug DiscoveryDilip Narayanan, Kim T Tran, Jakob S Pallesen, et al.Pageof 2